Breast Cancer

 

WBI Versus PBI for Women with Stage 0, I or II Breast Cancer (NSABP B-39)
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I or II Breast Cancer

Investigator: George Laramore, MD;   Conditions: Breast Cancer; Solid Tumors;    Status: Recruiting;   Study ID: NCT00103181

Ampligen w/Vaccine Therapy for Stage II-IV HER2-Positive Breast Cancer (7425)
Phase I-II Study of HER2 Vaccination with poly(I) poly(C12U) (Ampligen®) as an Adjuvant in Optimally Treated Breast Cancer Patients

Investigator: Lupe Salazar, MD;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01355393

I-SPY2 Trial (7518)
I-SPY2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and moLecular Analysis 2)

Investigator: Larissa Korde;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01042379

Early Assessment Challenge Grant (7043)
Imaging Early Response of ER+, HER2- Breast Cancer To Aromatase Inhibitor (AI) Therapy

Investigator: David Mankoff, M.D., PhD ;   Conditions: Breast Cancer;    Status: Recruiting

Whole Breast Irradiation with Hypofractionation versus standard Whole Breast Irradiation (RTOG 1005)
A Phase III clinical trial of Accelerated Whole Breast Irradiation with Hypofractionation plus concurrent boost versus standard Whole Breast Irradiation plus sequential boost for early-stage breast cancer.

Investigator: George Laramore, MD;   Conditions: Breast cancer;    Status: Recruiting;   Study ID: NCT01349322